These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 5042372)

  • 21. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 22. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 23. A clinico-biochemical correlation in a Parkinsonian patient treated with levodopa and decarboxylase inhibitor (Ro 4-4602). A model study.
    Sroka H; Eichhorn F; Rutenberg A; Radwan H; Bornstein B
    J Neurol Sci; 1972 Sep; 17(1):61-8. PubMed ID: 5057196
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 25. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine.
    Bartholini G; Pletscher A
    J Pharm Pharmacol; 1969 May; 21(5):323-4. PubMed ID: 4390126
    [No Abstract]   [Full Text] [Related]  

  • 29. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W; Danielcyk W; Neumayer E; Riederer P
    J Neural Transm; 1973; 34(2):133-43. PubMed ID: 4722571
    [No Abstract]   [Full Text] [Related]  

  • 30. Levodopa in the treatment of Parkinsonism.
    Cotzias GC
    JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
    [No Abstract]   [Full Text] [Related]  

  • 31. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
    Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
    J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
    [No Abstract]   [Full Text] [Related]  

  • 33. Modification of the cardiovascular effects of L-dopa in anesthetized dogs by inhibitors of enzymes involved in catecholamine metabolism.
    Robson RD
    Circ Res; 1971 Jun; 28(6):662-70. PubMed ID: 4325846
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
    Reid JL; Calne DB; Vakil SD; Allen JG; Davies CA
    J Neurol Sci; 1972 Sep; 17(1):45-51. PubMed ID: 4560435
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 37. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.
    Calne DB; Reid JL; Vakil SD; Rao S; Petrie A; Pallis CA; Gawler J; Thomas PK; Hilson A
    Br Med J; 1971 Sep; 3(5777):729-32. PubMed ID: 4938431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levadopa and pyridoxine.
    Mars H; Barrera ER; Bennett S
    JAMA; 1972 Mar; 219(13):1764. PubMed ID: 5067250
    [No Abstract]   [Full Text] [Related]  

  • 39. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of dopa decarboxylation by RO4-4602, MK 485 and MK 486 in human liver homogenates.
    Vogel WH; Mahoney K; Hare TA
    Arch Int Pharmacodyn Ther; 1972; 198(1):85-93. PubMed ID: 4538242
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.